Why the study?
Does Trasicor (a beta-adrenergic blocking drug) reduce the frequency and severity of angina attacks in patients with angina pectoris?
Does Trasicor (a beta-adrenergic blocking drug) reduce the frequency and severity of angina attacks in patients with angina pectoris?
Trasicor demonstrated efficacy in improving angina pectoris symptoms without observable side effects at doses up to 400 mg daily in a small patient cohort.
Answers are grounded in this paper and cite their sources.
Supports Trasicor for angina symptom control; confirms beta-blocker efficacy in this RCT.
Eighteen patients entered a double-blind trial of the beta-adrenergic blocking drug Trasicor in the treatment of angina pectoris. Six patients had to be withdrawn from the trial when substitution of placebo for Trasicor caused severe exacerbation of angina attacks. In these cases the frequency and severity of angina attacks fell to a minimum when Trasicor was re-established. A further 10 patients were significantly improved by Trasicor. Two patients showed no significant improvement. No side-effects were observed in doses ranging up to 400 mg. daily.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (1969) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: